Related Experiment Videos
[Interferon therapy of chronic hepatitis]
1First Dept. Internal Medicine, Univ. of Tokyo.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|August 1, 1992
Summary
Interferon therapy shows promise for chronic hepatitis C by eradicating viral RNA, achieving sustained remission in 40% of patients. However, its effectiveness against chronic hepatitis B is limited due to viral DNA replication.
Area of Science:
- Hepatology
- Virology
- Immunology
Context:
- Review of current interferon (IFN) therapy for chronic hepatitis B and C in Japan.
- IFN therapy induces 2'-5' oligoadenylate synthetase (2-5AS), activating RNAase to degrade viral RNA.
Purpose:
- To review the efficacy and limitations of interferon therapy for chronic viral hepatitis in Japan.
- To elucidate the mechanisms of IFN action against HBV and HCV.
Summary:
- IFN therapy reduces HBV DNA, HBeAg, and HBsAg in chronic hepatitis B, but viral replication resumes post-treatment due to unaffected viral DNA.
- For chronic hepatitis C, IFN suppresses viral protein and RNA production, eradicating HCV RNA and leading to sustained ALT normalization and HCV RNA negativity in approximately 40% of patients.
Impact:
- Highlights the differential efficacy of IFN therapy based on viral type (RNA vs. DNA).
- Suggests IFN therapy as a potentially curative option for a significant subset of chronic hepatitis C patients.
- Underscores the need for alternative or adjunct therapies for chronic hepatitis B due to IFN's limitations.